Accu chek glucose meter

After a 12-week intervention, glucose tolerance tests were performed in all mice injected with D-glucose (2 g/kg body weight) intraperitoneally after being fasted for 16 h (overnight, between 6 p.m. and 10 a.m.). For insulin tolerance tests, all mice were intraperitoneally injected with insulin (0.75 IU/kg body weight) after being fasted for 6 h (between 10 a.m. and 4 p.m.). Blood glucose levels were monitored at various time points (0, 15, 30, 60, and 120 min) with an ACCU-CHEK Glucose Meter (Roche Diabetes Care, Inc., Basel, Switzerland).

The presence of risk factors associated with raised BP and cardiovascular risk are determined using standardized questionnaires in face-to-face interviews performed by staff members with undergraduate degrees in nutrition, biomedicine, or biology. Evaluations are performed at the beginning and end of the study using standardized interviews on prior morbidity, drug use, eating habits, and lifestyle. At the clinic, measurements are taken of weight; height; waist, hip, and neck circumferences; estimated body composition (bioelectrical impedance analysis); electrocardiography; retinography; and laboratory evaluation of cholesterol and fractions, triglycerides, fasting glucose, glycated hemoglobin A_1c, creatinine, potassium, C-reactive protein, and urinary sodium. At home, measurements are taken of capillary glucose (before breakfast and dinner for 3 days; Accu-Chek glucose meter, Roche Diabetes Care Inc) and step count (Omron HJ-112 digital pocket pedometer, Omron Healthcare Inc) during the waking hours for 7 days. Participants have BP recorded in the office using an automatic oscillometric device and at home using a Spacelabs 90207 monitor (Spacelabs Healthcare).
In addition, participants are instructed not to change doses or type of antihypertensive medication during the trial.